Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $31.68, moving 3.21% from the previous trading session.
HIMS - Hims & Hers Health, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$29.67
DETAILS
HIGH:
$60.00
LOW:
$12.50
MEDIAN:
$25.00
CONSENSUS:
$29.67
DOWNSIDE:
6.34%
Stock News
Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced its Chief Accounting Officer, Irene Becklund will depart the company after more than seven years, effective October 9, 2026. Becklund will then serve as an advisor to the company for several months to assist with the transition. The company will conduct a search for her permanent successor, with Yemi Okupe, CFO of Hims & Hers, assuming the responsibilities of.
Hims & Hers Health, Inc. (HIMS) Outpaces Stock Market Gains: What You Should Know
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $35.15, moving +2.24% from the previous trading session.
Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter 2026 financial results after the market closes on Monday, August 10, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, refe.
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Health: The Market Still Doesn't Get It
FDA staff challenged seven compounded peptides, but Hims & Hers continues expanding internationally and strengthening its core healthcare platform beyond longevity therapies. The $400 million JPMorgan receivables facility improves financial flexibility, supporting GLP-1 expansion without relying on dilutive equity financing. The $1.15 billion Eucalyptus acquisition adds 850,000 customers and approximately $450 million of ARR across eight international markets.
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $36.17, moving 5.51% from the previous trading session.
Hims & Hers Health vs. Teladoc Health: Which Healthcare Stock Is a Better Buy in 2026?
Hims & Hers Health continues to drive impressive growth through its subscription-based consumer wellness platform. Teladoc Health maintains a dominant market share with over 100 million global members and significant institutional partnerships.
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
The healthcare sector is one of the best-performing sectors in the S&P 500 over the past month, with a gain of around 6%. But while that rebound has been led by a handful of mega-cap Big Pharma companies, it has also been reflected in the performances of smaller firms.
HIMS Breakout Signals Structural Business Transformation
The stock rebounded from below $14 after a regulatory shock and is now trading above $37 on a diversified growth narrative. Monthly weight-loss subscriber additions exceed one hundred thousand, transforming GLP-1 products into a powerful customer acquisition funnel. Peptides, AI healthcare systems, and international expansion create multi-layered optionality beyond traditional telehealth and pharmacy models.
Amplify Online Retail ETF Rides a Summer Surge in Performance
The Amplify Online Retail ETF (IBUY) has rallied over the past month, signaling a robust appetite for online consumer discretionary spending despite persistent macroeconomic headwinds. Outsized gains in specialized healthcare retail and online travel names have driven performance for IBUY's underlying index.
Hims & Hers stock jumps as Canaccord lifts target price ahead of FDA review
Hims & Hers Health shares (HIMS) surged 9% on Wednesday after Canaccord Genuity raised its price target on the telehealth company, citing improving sales trends, momentum in its weight-loss business, and growing optimism around its peptide opportunity. Canaccord analyst Maria Ripps maintained a Buy rating on the stock while increasing her price target to $40 from $32, implying additional upside from current levels.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Health, Inc. (HIMS) Stock Falls Amid Market Uptick: What Investors Need to Know
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $33.39, indicating a -1.62% shift from the previous trading day.
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
Hims' obesity drug business may get boost as employers drop coverage
Telehealth provider Hims and Hers Health may get a boost next year from employers dropping coverage of weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo to rein in costs, investors and analysts say.
Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $32.96, moving 1.73% from the previous trading session.
A Look at Hims & Hers Health Inc (HIMS) After 5.4% Decline -- GF Value $38.53 vs Price $33.54
On June 22, 2026, Hims and Hers Health Inc (HIMS) shares fell 5.4% today, trading at $33.54. Over the past 52 weeks, the stock has ranged from a low of $13.74 to
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Stock Jumps After Barclays Raises Price Target
Hims & Hers Health Inc. (NYSE:HIMS) shares are climbing after Barclays reiterated its bullish stance and lifted its price target from $29 to $39. Here's what you need to know.
Price Targets
Hims and Hers (HIMS) PT Raised to $37 at BofA Securities
$37.00
(was $36.07)
UBS
Hims & Hers price target raised to $40 from $32 at Canaccord
$40.00
(was $34.67)
Canaccord Genuity
Hims & Hers price target raised to $39 from $29 at Barclays
$39.00
(was $31.89)
Barclays
Leerink Reiterates Market Perform Rating on Hims and Hers (HIMS)
$25.00
(was $27.64)
Michael Cherny
·
Leerink Partners
Hims and Hers (HIMS) PT Lowered to $25 at BofA Securities
$25.00
(was $23.75)
UBS
Hims & Hers price target raised to $23 from $18 at Truist
$23.00
(was $23.88)
UBS
Hims & Hers price target lowered to $24.50 from $25.50 at Jefferies
$24.50
(was $25.28)
Jefferies
Hims & Hers price target raised to $35 from $30 at Needham
$35.00
(was $25.22)
UBS
Hims & Hers price target raised to $32 from $30 at Canaccord
$32.00
(was $29.14)
Canaccord Genuity
Hims & Hers price target lowered to $25 from $28 at Deutsche Bank
$25.00
(was $26.19)
George Hill
·
Deutsche Bank
Hims & Hers price target raised to $28 from $25 at Deutsche Bank
$28.00
(was $23.47)
Deutsche Bank
Needham Upgrades Hims and Hers (HIMS) to Buy
$30.00
(was $22.35)
Ryan MacDonald
·
Needham
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS) amid Novo partnership
$12.50
(was $21.58)
Oppenheimer
Hims & Hers price target lowered to $25 from $48 at Barclays
$25.00
(was $15.90)
Barclays
Hims & Hers price target lowered to $21 from $40 at Morgan Stanley
$21.00
(was $14.38)
Craig Hettenbach
·
Morgan Stanley
Hims & Hers price target lowered to $24 from $33 at Evercore ISI
$24.00
(was $14.10)
Evercore ISI
Hims & Hers price target lowered to $18 from $37 at Truist
$18.00
(was $15.51)
Jailendra Singh
·
Truist Financial
Hims & Hers price target lowered to $17.50 from $20 at Leerink
$17.50
(was $15.51)
Leerink Partners
Hims & Hers price target lowered to $31 from $42 at Deutsche Bank
$31.00
(was $18.25)
George Hill
·
Deutsche Bank
Hims and Hers (HIMS) PT Lowered to $20 at Leerink Partners
$20.00
(was $17.35)
Michael Cherny
·
Leerink Partners